![PDF) 2017 KASL clinical practice guidelines management of hepatitis C: Treatment of chronic hepatitis C PDF) 2017 KASL clinical practice guidelines management of hepatitis C: Treatment of chronic hepatitis C](https://i1.rgstatic.net/publication/328293966_2017_KASL_clinical_practice_guidelines_management_of_hepatitis_C_Treatment_of_chronic_hepatitis_C/links/5c04475f299bf1a3c15e1bf6/largepreview.png)
PDF) 2017 KASL clinical practice guidelines management of hepatitis C: Treatment of chronic hepatitis C
![PDF) New insights on the pharmacogenomics of antidepressant response from the GENDEP and STAR*D studies: rare variant analysis and high-density imputation PDF) New insights on the pharmacogenomics of antidepressant response from the GENDEP and STAR*D studies: rare variant analysis and high-density imputation](https://i1.rgstatic.net/publication/345173765_New_insights_on_the_pharmacogenomics_of_antidepressant_response_from_the_GENDEP_and_STARD_studies_rare_variant_analysis_and_high-density_imputation/links/5fec8b3992851c13fed436be/largepreview.png)
PDF) New insights on the pharmacogenomics of antidepressant response from the GENDEP and STAR*D studies: rare variant analysis and high-density imputation
![PDF) A 6-Month Open-Label Extension Study of Vortioxetine in Pediatric Patients with Depressive or Anxiety Disorders PDF) A 6-Month Open-Label Extension Study of Vortioxetine in Pediatric Patients with Depressive or Anxiety Disorders](https://i1.rgstatic.net/publication/320435896_A_6-Month_Open-Label_Extension_Study_of_Vortioxetine_in_Pediatric_Patients_with_Depressive_or_Anxiety_Disorders/links/5a73bde0458515512077dca7/largepreview.png)